Acceptability of advanced Controlled Human Infection Models; the case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi

This study conducted in Malawi reveals that while people living with HIV and the broader community generally accept the use of advanced Controlled Human Infection Models for pneumococcal and tuberculosis research, they emphasize the critical need for robust safety measures, informed consent, and culturally sensitive community engagement.

The Gist

Imagine you are trying to invent a new, better shield to protect a village from a dangerous storm. To test if your shield works, you need to see how the storm actually hits it. But you can't just wait for a real storm to hit the whole village and hope for the best; that would be too dangerous and chaotic.

This paper is about a group of researchers in Malawi asking the village elders, the families, and the local leaders a very important question: "Would you be willing to let a few brave volunteers step out into a small, controlled version of the storm so we can learn how to build better shields for everyone?"

Here is the breakdown of their conversation, explained simply:

1. The Big Idea: The "Controlled Storm" (CHIM)

The researchers are talking about Controlled Human Infection Models (CHIM). Think of this as a simulated fire drill for diseases.

• How it works: Instead of waiting for people to get sick naturally (which is unpredictable and dangerous), scientists carefully introduce a tiny, safe amount of a germ to a volunteer in a hospital setting.
• The Goal: They watch exactly how the body fights it. This helps them figure out which vaccines or medicines work best, much faster than waiting for a natural outbreak.

2. The Two New Challenges

Usually, these "fire drills" are done on healthy, strong adults. But the researchers wanted to try two new, tricky scenarios:

• Scenario A: The "Weakened Shield" (People with HIV): People living with HIV have immune systems that are a bit more fragile, like a shield with a few cracks. The researchers wanted to test a pneumonia vaccine specifically on them because they are at high risk.
• Scenario B: The "Silent Enemy" (Tuberculosis): Tuberculosis (TB) is a huge problem in Malawi. The researchers wanted to test a new TB vaccine. To start safely, they proposed using BCG (the childhood TB vaccine everyone knows) as a "practice run" before trying the real, more dangerous TB germ.

3. The Village Meeting (The Study)

The researchers didn't just decide this in a lab. They held 14 town hall meetings (Focus Groups) and 8 private chats (Interviews) with 114 people.

• Who was there? People living with HIV, former TB patients, local chiefs, religious leaders, nurses, and people who had never done research before.
• The Vibe: It was an open, honest conversation about fears, hopes, and rules.

4. What Did the Village Say? (The Results)

Overall, the village said "Yes, but..." They were supportive but had very practical concerns.

The "Yes" (The Green Lights):

• Trust: The community trusts the researchers (the Malawi-Liverpool Wellcome team) because they have done good work before. It's like trusting a mechanic who has fixed your car for years.
• Pride: Many felt a sense of national pride. They wanted to be the ones to help solve the TB and HIV problems that plague their country.
• Necessity: They understood that without these "fire drills," new medicines might take forever to arrive.

The "But" (The Yellow and Red Lights):

• Safety First: For the HIV group, everyone agreed: "Only let the strongest, healthiest people with HIV join. Don't risk the very sick." They wanted strict health checks (like checking the "battery level" of their immune system) before anyone signed up.
• The "Scary Needle" (Biopsies): For the TB study, they were worried about taking small skin samples (biopsies).
  • The Fear: Some worried about scars or pain.
  • The Myth: Some had old-fashioned fears that the tissue might be used for bad magic or rituals. The researchers realized they need to explain clearly: "This tissue is just for science, it goes in a safe box, and it won't be used for anything else."
• The "Sleepover" (Residential Stay): Participants had to stay at a research center for a few days.
  • The Worry: Women were worried about leaving their children and what the neighbors would gossip about. "Why is she staying away? Is she sick?"
  • The Fix: The researchers promised to provide food, water, and a safe, comfortable place so it feels like a retreat, not a prison.
• Money and Fairness: In a poor country, money is a big deal. If the researchers offer too much money, it might trick poor people into saying "yes" even if they are scared (like a "bribe"). If they offer too little, it feels unfair. The community wants a fair "thank you" for their time and risk, not a trap.

5. The Takeaway

The paper concludes that the community is ready. They are willing to be the "guinea pigs" (in a respectful way) to help save their neighbors, provided that:

1. Safety is the #1 rule.
2. Everyone understands what is happening (no confusing medical jargon).
3. They are treated with dignity and not judged by their neighbors.

In short: The researchers asked, "Can we test these new vaccines on you?" The community replied, "Yes, we will help you build the shield, but you must promise to keep us safe, explain everything clearly, and treat us like partners, not just test subjects."

Technical Summary

1. Problem Statement

Controlled Human Infection Models (CHIM), also known as human challenge studies, are critical tools for accelerating vaccine and therapeutic development by deliberately exposing volunteers to pathogens. While historically conducted in healthy adults in high-income settings, there is a scientific imperative to expand CHIMs to:

• At-risk populations: Specifically People Living with HIV (PLHIV), who are highly susceptible to pneumococcal disease and excluded from current vaccination programs in sub-Saharan Africa.
• Complex pathogens: Specifically Tuberculosis (TB), which poses high risks and stigma. While attenuated strains like Bacillus Calmette-Guérin (BCG) are used as intermediate steps, the acceptability of "TB CHIMs" in endemic, low-resource settings has not been explored.

The Core Gap: There is a lack of data regarding community and stakeholder acceptability, ethical concerns, and practical feasibility of conducting advanced CHIMs involving PLHIV and mycobacterial challenges in Malawi, a high-burden setting.

2. Methodology

The study employed a qualitative research design under the ACHIMA (Advanced CHIM Acceptability) programme, part of the Malawi Accelerated Research in Vaccines, Experimental and Laboratory Systems (MARVELS) consortium.

• Study Design: A mixed-methods qualitative approach utilizing Focus Group Discussions (FGDs) and In-Depth Interviews (IDIs).
• Participants: A purposive, maximum-variety sample of 114 stakeholders (106 in FGDs, 8 in IDIs) recruited between December 2023 and June 2024.
  • Groups included: PLHIV (from clinics), former TB patients, healthy community members, former CHIM participants, community opinion leaders (chiefs), religious leaders, Community Advisory Group (CAG) members, HIV/TB clinicians, and Health Surveillance Assistants (HSAs).
  • Expert IDIs: HIV/TB clinician scientists and local Research Ethics Committee (REC) members.
• Data Collection:
  • Separate FGDs were held for specific groups to manage power dynamics, though men and women were mixed within groups.
  • Topics were split into two distinct streams: (1) Pneumococcal CHIM in PLHIV and (2) Mycobacterial (BCG) CHIM in HIV-negative adults.
  • Sessions were conducted in Chichewa, audio-recorded, transcribed, and translated.
• Analysis: Thematic and framework analysis using NVivo 14. Themes were derived both deductively (recruitment, ethics) and inductively from the data.

3. Key Contributions

• First Community Assessment in Malawi: This is the first study to systematically evaluate community views on CHIMs involving vulnerable populations (PLHIV) and complex pathogens (TB/BCG) in a high-burden African setting.
• Differentiated Risk Perception: The study distinguishes between the acceptability of different CHIM types, highlighting that while general CHIMs are accepted, specific procedural concerns (e.g., biopsies, bronchoscopy) and population-specific vulnerabilities (PLHIV) require tailored ethical frameworks.
• Cultural and Gender Insights: It provides granular data on how gender roles, childcare responsibilities, and cultural beliefs (e.g., myths regarding tissue collection) impact recruitment and retention in Malawi.
• Trust Dynamics: It identifies a unique trust hierarchy where the Malawi-Liverpool Wellcome Programme (MLW) enjoys significantly higher trust than local government health services, a critical finding for future public health interventions.

4. Key Results

Four primary themes emerged from the analysis:

A. General Acceptability and Motivation

• There is broad support for CHIM studies in Malawi. Participants view the potential benefits (new vaccines/treatments) as outweighing the risks.
• Trust in MLW: Participants with prior research experience expressed high confidence in the MLW programme, contrasting sharply with skepticism toward local government health services.
• National Pride: Participation is often motivated by a desire to contribute to national health solutions and reduce the burden of diseases like TB and pneumococcal disease.

B. Recruitment and Consent Challenges

• Literacy and Misinformation: Low literacy levels and widespread misinformation (e.g., rumors of population control or cholera from vaccines) are major barriers.
• Gender Disparities: While participants believed men might be easier to recruit due to literacy, actual data from the authors' previous work suggests women are often more willing to participate in clinical settings. However, women face specific barriers regarding childcare and the requirement for contraception during studies.
• Compensation: Determining fair compensation in a resource-poor context is complex. Participants emphasized that incentives must balance economic needs with the risk of "over-recruitment" or coercion.

C. Practical Considerations (Residential & Safety)

• Residential Stays: Participants supported staying in a conference center for monitoring but expressed concern about loss of income and the reputational risk (stigma/gossip) for women staying away from home.
• Healthcare Access: There is a strong demand for guaranteed, high-quality healthcare during and after the study, driven by the general lack of access to care in Malawi.

D. Specific Study Concerns

• Pneumococcal CHIM in PLHIV: Participants expressed concern for the clinical vulnerability of PLHIV. They insisted on strict inclusion criteria, specifically requiring high CD4 counts and viral suppression to ensure safety.
• TB/BCG CHIM: There was strong support for BCG challenges due to familiarity with the vaccine. However, specific procedures raised alarms:
  • Skin Biopsy: Concerns regarding pain, scarring (cosmetic impact), and delayed healing, particularly for women.
  • Tissue Collection: Fears rooted in local myths about tissue being used for rituals or harmful practices.
  • Bronchoscopy: Viewed as highly invasive and risky, despite the research team's 28-year history of safe bronchoscopy use.

5. Significance

• Ethical Framework Development: The study provides the empirical basis for developing ethical guidelines and safety caveats for advanced CHIMs in sub-Saharan Africa. It confirms that while the community supports the science, the implementation must be rigorously adapted to local cultural and economic realities.
• Strategic Recruitment: It highlights the need for mass awareness campaigns (radio, TV, community leaders) to combat misinformation and the necessity of gender-specific recruitment strategies.
• Future Research Pathway: The findings validate the feasibility of proceeding with a BCG CHIM as a safe intermediate step toward a full TB CHIM, provided that concerns regarding biopsies and tissue handling are addressed through transparent communication.
• Policy Impact: The results suggest that for CHIMs to succeed in Malawi, researchers must address "therapeutic misconceptions" (ensuring participants do not view the study solely as a source of free healthcare) and ensure long-term post-study care commitments are met.

In conclusion, the paper demonstrates that the Malawian community is ready to engage in advanced CHIM research, provided that safety, informed consent, cultural sensitivity, and fair compensation are prioritized. The study serves as a blueprint for conducting ethically robust human challenge trials in low-resource, high-disease-burden settings.